Positive urinary antigen tests for Streptococcus pneumoniae in community-acquired pneumonia: a 7-year retrospective evaluation of health care cost and treatment consequences
- 31 October 2012
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 32 (4) , 485-492
Abstract
A positive pneumococcal urinary antigen test (PUAT) for Streptococcus pneumoniae allows an early switch from empiric to targeted treatment in hospitalised community-acquired pneumonia (CAP) patients. The economic and treatment consequences of this widespread implemented test are, however, unknown. We retrospectively evaluated all tests performed since its introduction in two teaching hospitals. Data on patient characteristics, treatment, admission and outcome were retrieved from the electronic patient files. Test benefits were expressed as the number of days that targeted therapy (i.e. penicillin) was administered to hospitalised CAP patients due to a positive PUAT. This calculation was based on the timing of the PUAT and the initiation of targeted therapy. Subsequently, we performed two direct cost analyses from a hospital perspective, first including tests performed for CAP only, and second including costs of all (excessive) tests. Between 2005 and 2012, 3,479 PUATs were performed, of which 1,907 (55 %) were for CAP. A total of 1,638 PUATs (86 %) were negative and 269 (14 %) were positive. Fifty-two (19 %) positive tests were excluded. In 75 (35 %) of the 217 remaining positive tests, a positive PUAT led to targeted treatment during 293 cumulative admission days. Testing costs for CAP only were €131 per targeted treatment day. These costs were €257 if local protocol dictated PUAT use for all CAP cases, as opposed to €72 if the test was reserved for severe cases only. When including all tests, PUAT costs were €254 per targeted treatment day. Therefore, improving the selective use of the PUAT in hospitalised CAP patients may lead to increased (cost-)efficiency.Keywords
This publication has 18 references indexed in Scilit:
- The role of intestinal colonization with Gram-negative bacteria as a source for intensive care unit-acquired bacteremia*Critical Care Medicine, 2011
- Do clinicians consider the results of the BinaxNOW Streptococcus pneumoniae urinary antigen test when adapting antibiotic regimens for pneumonia patients?Clinical Microbiology and Infection, 2010
- BTS guidelines for the management of community acquired pneumonia in adults: update 2009Thorax, 2009
- Point-of-care urinary pneumococcal antigen test in the emergency department for community acquired pneumoniaEmergency Medicine Journal, 2008
- Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in AdultsClinical Infectious Diseases, 2007
- Evaluating the Use of a Streptococcus pneumoniae Urinary Antigen Detection Kit for the Management of Community-Acquired Pneumonia in JapanRespiration, 2006
- Role of beta-lactam agents in the treatment of community-acquired pneumoniaEuropean Journal of Clinical Microbiology & Infectious Diseases, 2005
- Algorithm To Determine Cost Savings of Targeting Antimicrobial Therapy Based on Results of Rapid Diagnostic TestingJournal of Clinical Microbiology, 2003
- Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation studyThorax, 2003
- A Prediction Rule to Identify Low-Risk Patients with Community-Acquired PneumoniaNew England Journal of Medicine, 1997